Navigation Links
Study gives clues to how adrenal cancer forms

ANN ARBOR, Mich. At the ends of chromosome are special pieces of DNA called telomeres. Think of it as the little tip that caps off a shoelace. The telomeres send signals to the cells to let them know it's the end point, not a break that should be repaired.

Over time, as cells reproduce, the telomeres become shorter and eventually no longer do their job. The cells then have a higher risk of mutating into cancer.

But, a new study finds, if the telomere becomes dysfunctional at any point regardless of shortening it can trigger a cancer event. The study, by researchers at the University of Michigan Comprehensive Cancer Center, was done in mice generally prone to develop cancer. The mice that also had dysfunctional telomeres were particularly prone to develop the usually ultra-rare adrenocortical cancer. This is the first mouse model to specifically address this rare but lethal type of cancer.

"Usually when telomeres get short, they also seem to get deprotected. No one's been able to say if it's the shortening or the deprotection that causes cancer to arise. In this study, we were able to show that deprotection alone, even in the absence of a short telomere, is enough to trigger cancer. This may be a general mechanism of adrenal cancer as well as many other cancers in the body," says study author Gary Hammer, M.D., Ph.D., the Millie Schembechler Professor of Adrenal Cancer at the U-M Comprehensive Cancer Center.

Results of the study appear in the June issue of Cancer Cell.

The researchers also found that a protein called p53 usually prevents the cancer trigger. P53 is critical to the cell destruction process. When it's missing, cells replicate uncontrolled, the hallmark of cancer. In this study, the researchers eliminated p53 in the mice and found that the dysfunctional telomeres then tried to repair themselves. This led to breaks in the chromosome, causing scrambled genes and mutations.

"P53 mutation together with telomere dysfunction may be the basis for the genomic changes we see in adrenal cortical cancer and other malignancies," says study author Tobias Else, M.D., a post-doctoral fellow and Garry Betty Scholar in Adrenal Cortical Cancer Research at the U-M Comprehensive Cancer Center.

Adrenal cancer is extremely rare -- about 600 new cases are diagnosed each year in the United States. It is typically diagnosed in late stages when there is nearly no chance of survival beyond five years. Researchers hope that a better understanding of how the disease develops will help lead to new treatments for a cancer type that gets little to no attention and limited research funding.

"This work proves a basic science principle and gives us understanding of how these genetic changes occur to give us this cancer. But it is not just limited to adrenal cancer. Our research started with the adrenal gland, but we saw tumors form in multiple parts of the body. This will be of broader interest to the scientific community," Else says.


Contact: Nicole Fawcett
University of Michigan Health System

Related medicine news :

1. Protein may be strongest indicator of rare lung disease, study shows
2. People who wear rose-colored glasses see more, University of Toronto study shows
3. 5 Spanish centers join a study for a new leukemia and lymphoma treatment technique
4. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
5. FDA to Study Ways to Be More Open With Public
6. Study further expands understanding of leptins role in brain neurocircuitry
7. NASA Selects Four Proposals to Study Space Radiation Risks
8. Study Results Show CAQH CORE Certification Dramatically Cuts Administrative Costs, Accelerates I.T. Adoption by Providers and Health Plans
9. Study: Benefit to women not enough to sway men to get HPV vaccine
10. New study shows people with mental health problems receive inadequate medical care
11. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Post Your Comments:
Related Image:
Study gives clues to how adrenal cancer forms
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: